+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ulcerative Colitis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Ulcerative Colitis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Ulcerative Colitis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 4985922
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ulcerative Colitis Market grew from USD 8.14 billion in 2024 to USD 8.93 billion in 2025. It is expected to continue growing at a CAGR of 9.44%, reaching USD 14.00 billion by 2030.

Ulcerative colitis (UC) remains a formidable chronic inflammatory disorder of the colon, imposing significant clinical and economic burdens worldwide. Over the past decade, rapid scientific advances and evolving patient expectations have driven shifts in therapeutic paradigms, regulatory frameworks, and health-care delivery models. Stakeholders-from pharmaceutical innovators to payers and providers-must navigate an increasingly complex environment defined by novel biologic therapies, the emergence of biosimilars, and intensifying cost pressures.

This executive summary presents a comprehensive overview of the current ulcerative colitis landscape, highlighting transformative industry shifts, the impending effects of U.S. tariffs, sophisticated market segmentation, regional dynamics, and the strategic positioning of leading players. By synthesizing the latest insights, this report aims to inform executives, clinical decision-makers, and investors on actionable levers that will drive sustainable growth and optimize patient outcomes in 2025 and beyond.

Key Transformative Shifts Reshaping Ulcerative Colitis Management

The past few years have witnessed several pivotal shifts reshaping ulcerative colitis management. First, the maturation of biologic therapies-particularly anti-TNF agents, anti-integrin antibodies, and interleukin-targeted inhibitors-has elevated standards of care while fostering competition and price negotiation.

Simultaneously, biosimilar approvals have created downward pricing pressure and enhanced access, prompting originator manufacturers to differentiate through patient support programs and real-world evidence generation. Next, digital health platforms and remote monitoring tools have gained traction in maintaining long-term remission and reducing hospitalizations.

Moreover, regulatory agencies have embraced adaptive pathways and expedited review processes for therapies addressing unmet needs, accelerating time to market. Finally, the shift toward value-based contracting underscores a growing emphasis on real-world outcomes and total cost of care, driving collaboration between manufacturers, payers, and providers. Together, these transformative forces are redefining stakeholder expectations and setting the stage for future innovation in ulcerative colitis treatment.

Cumulative Impact of United States Tariffs in 2025 on Costs and Access

In 2025, newly imposed United States tariffs on imported pharmaceuticals are poised to significantly affect cost structures and patient access. Tariffs on active pharmaceutical ingredients and finished biologic products will increase the landed cost of originator therapies such as monoclonal antibodies and interleukin inhibitors, potentially driving price adjustments at the pharmacy counter.

Manufacturers may seek to offset higher import duties through supply chain localization, onshoring, or entering into strategic partnerships with domestic contract manufacturing organizations. However, these measures require lead time and capital investment, which could delay broader availability of advanced therapies.

Conversely, tariff-driven price increases may accelerate biosimilar uptake as health plans and health systems intensify efforts to manage pharmacy spend. Generic small-molecule drugs, particularly aminosalicylates and corticosteroids, may see modest price inflation, but their overall affordability is likely to maintain widespread access. Overall, tariff-induced market distortions in 2025 will compel stakeholders to adopt more agile sourcing strategies, reinforce cost-containment initiatives, and advocate for policy adjustments to safeguard patient affordability.

Comprehensive Insights from Advanced Market Segmentation

A nuanced segmentation framework reveals critical insights into competitive dynamics and growth pockets. When analyzing product type, three major categories emerge: Biologics, Biosimilars, and Drugs. The Biologics segment encompasses Anti-Integrin Agents such as vedolizumab, Anti-TNF Agents such as adalimumab and infliximab, and IL-12 and IL-23 inhibitors such as ustekinumab. Biosimilars split into marketed and pipeline candidates, increasingly challenging high-cost originators. Meanwhile, the Drugs category spans aminosalicylates, corticosteroids, and immunomodulators, the latter including azathioprine and mercaptopurine, reflecting a continuum from first-line to steroid-sparing regimens.

By treatment type, the market differentiates between induction therapy-targeting both mild-to-moderate and severe ulcerative colitis-maintenance therapy, which divides into corticosteroid and non-corticosteroid approaches, and surgical treatments, notably ileal pouch-anal anastomosis (IPAA) and proctocolectomy. This stratification underscores distinct clinical pathways and resource allocations for acute remission induction versus long-term disease control.

Patient population segmentation further refines market understanding. Adult cohorts encompass elderly patients aged 56 and above, middle-aged individuals between 36 and 55, and young adults from 19 to 35, each with unique comorbidity profiles and adherence challenges. Pediatric patients include children aged three to 12 and infants from birth to two years, highlighting the need for age-appropriate dosing, safety monitoring, and caregiver support.

Pricing analysis separates generic drugs, including over-the-counter formulations, from prescription medications, which can be insurance covered or non-insurance covered. This lens reveals payer preferences and formulary placement dynamics. Finally, distribution channels span hospital pharmacies, online pharmacies, and retail pharmacies, the latter divided into chains and independents, indicating varied purchasing behaviors and promotional strategies across inpatient and outpatient settings.

Strategic Regional Dynamics Driving Market Growth

Regional dynamics play a pivotal role in shaping market opportunities and challenges across the Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific. In the Americas, robust private-sector investment and established value-based care models facilitate rapid adoption of innovative biologics and digital health solutions. Payer-provider collaborations have streamlined access programs, while public payers focus on biosimilar substitution to control pharmacy expenditures.

Across EMEA, regulatory harmonization under initiatives such as the European Medicines Agency’s adaptive pathways has accelerated product approvals, creating a competitive biosimilar marketplace. National health services leverage tender processes to negotiate aggressive pricing, fostering broad patient access but intensifying margin pressures for manufacturers.

In Asia-Pacific, rising ulcerative colitis incidence, particularly in urban centers, is driving demand for cost-effective therapies and localized manufacturing. Countries such as Japan and Australia adopt a hybrid approach, blending innovative biologics with generics and biosimilars, whereas emerging markets prioritize affordability through strategic partnerships and technology transfers. Ultimately, each region’s unique reimbursement environment, regulatory landscape, and health-care infrastructure will dictate tailored market entry and expansion strategies.

Leading Industry Players and Their Strategic Focus

Leading pharmaceutical and biotech companies are deploying diverse strategies to secure competitive advantage. Abbott Laboratories has intensified investment in biosimilar development and patient affordability programs. AbbVie Inc. continues to defend its flagship anti-TNF franchise against incoming biosimilars while diversifying its pipeline into novel mechanisms.

AstraZeneca PLC is leveraging its biologics expertise to explore combination regimens and localized manufacturing in key markets. Bausch Health Companies Inc. focuses on generics and over-the-counter formulations to maintain volume-driven revenue streams. BioLineRx Ltd has advanced multiple clinical programs targeting inflammatory pathways beyond TNF and integrins.

Boehringer Ingelheim GmbH is deploying precision medicine approaches to identify biomarkers for therapeutic responsiveness. Celgene Corporation (now part of Bristol-Myers Squibb) remains committed to immunomodulator enhancements and patient support networks. Circle33, LLC is optimizing digital patient engagement platforms to improve adherence and real-world data capture.

Cosmo Pharmaceuticals NV emphasizes gastrointestinal-specialty formulations, while Eli Lilly and Company and GlaxoSmithKline Plc pursue anti-interleukin and small-molecule innovations. Johnson & Johnson Services, Inc. leverages its broad portfolio across immunology to offer holistic patient solutions. Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation are advancing next-generation biologics and cell-based therapies. Pfizer Inc. focuses on supply-chain efficiency and cost management, and Sanofi SA explores IL-23 inhibition and co-formulation strategies to differentiate its offerings.

Actionable Recommendations for Industry Leaders

To navigate the evolving ulcerative colitis landscape, industry leaders should prioritize the following actions:
  • Accelerate biosimilar development and launch readiness by forging strategic partnerships with contract manufacturers and leveraging real-world evidence to support adoption.
  • Implement value-based contracting models tied to patient outcomes, aligning incentives with payers and providers to demonstrate cost effectiveness and secure favorable formulary positioning.
  • Expand digital health capabilities by integrating remote monitoring, telemedicine, and patient engagement applications to enhance adherence, monitor safety, and collect longitudinal data.
  • Optimize global supply chains through geographic diversification, onshore manufacturing, and advanced analytics to mitigate tariff impacts and ensure uninterrupted product availability.
  • Tailor market entry strategies by region and segment, leveraging localized reimbursement pathways, adaptive regulatory frameworks, and targeted distribution channel partnerships to maximize reach.
By executing these recommendations, stakeholders can strengthen competitive positioning, reduce total cost of care, and ultimately improve patient outcomes in ulcerative colitis management.

Conclusion: Navigating the Next Phase of Ulcerative Colitis Care

As the ulcerative colitis market continues to evolve under the influence of novel therapeutics, regulatory shifts, and cost pressures, stakeholders must adopt integrated, patient-centric strategies. The convergence of innovative biologics, expanding biosimilar portfolios, and digital health solutions offers unprecedented opportunities to enhance treatment pathways. However, rising tariff burdens and intensifying price competition necessitate agile supply-chain management and value demonstration.

By leveraging advanced segmentation, region-specific insights, and competitive intelligence on leading companies, decision-makers can identify high-impact growth areas and optimize resource allocation. Collaboration across industry, payers, and regulatory authorities will be essential to foster sustainable access models, support evidence-generation efforts, and drive continuous innovation. Ultimately, a balanced approach that prioritizes clinical efficacy, economic value, and patient experience will define success in the next phase of ulcerative colitis care.

Market Segmentation & Coverage

This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
    • Anti-Integrin Agents
      • Vedolizumab
    • Anti-TNF Agents
      • Adalimumab
      • Infliximab
    • IL-12 and IL-23 Inhibitors
      • Ustekinumab
  • Biosimilars
    • Marketed Biosimilars
    • Pipeline Biosimilars
  • Drugs
    • Aminosalicylates
    • Corticosteroids
    • Immunomodulators
      • Azathioprine
      • Mercaptopurine
  • Induction Therapy
    • Mild-to-Moderate Ulcerative Colitis
    • Severe Ulcerative Colitis
  • Maintenance Therapy
    • Corticosteroid Treatment
    • Non-Corticosteroid Treatment
  • Surgical Treatments
    • Ileal Pouch-Anal Anastomosis (IPAA)
    • Proctocolectomy
  • Adult
    • Elderly
      • 56+ Years
    • Middle-Aged
      • 36-55 Years
    • Young Adults
      • 19-35 Years
  • Pediatric
    • Children
      • 3-12 Years
    • Infants
      • 0-2 Years
  • Generic Drugs
    • Over-the-Counter
  • Prescription Medications
    • Insurance Covered
    • Non-Insurance Covered
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
    • Chains
    • Independents

This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Ulcerative Colitis Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ulcerative Colitis Market, by Product Type
8.1. Introduction
8.2. Biologics
8.2.1. Anti-Integrin Agents
8.2.1.1. Vedolizumab
8.2.2. Anti-TNF Agents
8.2.2.1. Adalimumab
8.2.2.2. Infliximab
8.2.3. IL-12 and IL-23 Inhibitors
8.2.3.1. Ustekinumab
8.3. Biosimilars
8.3.1. Marketed Biosimilars
8.3.2. Pipeline Biosimilars
8.4. Drugs
8.4.1. Aminosalicylates
8.4.2. Corticosteroids
8.4.3. Immunomodulators
8.4.3.1. Azathioprine
8.4.3.2. Mercaptopurine
9. Ulcerative Colitis Market, by Treatment Type
9.1. Introduction
9.2. Induction Therapy
9.2.1. Mild-to-Moderate Ulcerative Colitis
9.2.2. Severe Ulcerative Colitis
9.3. Maintenance Therapy
9.3.1. Corticosteroid Treatment
9.3.2. Non-Corticosteroid Treatment
9.4. Surgical Treatments
9.4.1. Ileal Pouch-Anal Anastomosis (IPAA)
9.4.2. Proctocolectomy
10. Ulcerative Colitis Market, by Patient Population
10.1. Introduction
10.2. Adult
10.2.1. Elderly
10.2.1.1. 56+ Years
10.2.2. Middle-Aged
10.2.2.1. 36-55 Years
10.2.3. Young Adults
10.2.3.1. 19-35 Years
10.3. Pediatric
10.3.1. Children
10.3.1.1. 3-12 Years
10.3.2. Infants
10.3.2.1. 0-2 Years
11. Ulcerative Colitis Market, by Pricing Analysis
11.1. Introduction
11.2. Generic Drugs
11.2.1. Over-the-Counter
11.3. Prescription Medications
11.3.1. Insurance Covered
11.3.2. Non-Insurance Covered
12. Ulcerative Colitis Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.4.1. Chains
12.4.2. Independents
13. Americas Ulcerative Colitis Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Ulcerative Colitis Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Ulcerative Colitis Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. AbbVie Inc.
16.3.3. AstraZeneca PLC
16.3.4. Bausch Health Companies Inc.
16.3.5. BioLineRx Ltd
16.3.6. Boehringer Ingelheim GmbH
16.3.7. Celgene Corporation
16.3.8. Circle33, LLC
16.3.9. Cosmo Pharmaceuticals NV
16.3.10. Eli Lilly and Company
16.3.11. GlaxoSmithKline Plc
16.3.12. Johnson & Johnson Services, Inc.
16.3.13. Merck & Co., Inc.
16.3.14. Mitsubishi Tanabe Pharma Corporation
16.3.15. Pfizer Inc.
16.3.16. Sanofi SA
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ULCERATIVE COLITIS MARKET MULTI-CURRENCY
FIGURE 2. ULCERATIVE COLITIS MARKET MULTI-LANGUAGE
FIGURE 3. ULCERATIVE COLITIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY VEDOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MARKETED BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PIPELINE BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MILD-TO-MODERATE ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SEVERE ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROID TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY NON-CORTICOSTEROID TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ILEAL POUCH-ANAL ANASTOMOSIS (IPAA), BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 56+ YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 36-55 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 19-35 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 3-12 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 0-2 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INSURANCE COVERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY NON-INSURANCE COVERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CHAINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INDEPENDENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. CANADA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 157. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 158. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 159. CANADA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. CANADA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 161. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 162. CANADA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 163. CANADA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. CANADA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 165. CANADA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 166. CANADA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 167. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 168. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 169. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 170. CANADA ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 171. CANADA ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 172. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 173. CANADA ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 174. CANADA ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 175. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 176. CANADA ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 177. CANADA ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 178. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. CANADA ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 184. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 185. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 186. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 187. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 190. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 191. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 192. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 193. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 194. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 195. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 196. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 197. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 198. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 199. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 200. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 203. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 282. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. CHINA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 284. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 285. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 286. CHINA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. CHINA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 288. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 289. CHINA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 290. CHINA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. CHINA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 292. CHINA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 293. CHINA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 294. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 295. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 296. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 297. CHINA ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 298. CHINA ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 299. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 300. CHINA ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 301. CHINA ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 302. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 303. CHINA ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 304. CHINA ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 305. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. CHINA ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 307. INDIA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. INDIA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 309. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 310. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 311. INDIA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 312. INDIA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 313. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 314. INDIA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 315. INDIA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 316. INDIA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 317. INDIA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 318. INDIA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 319. INDIA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT POPULATION, 2018-2030 (USD MILLION)
TABLE 320. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 321. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ELDERLY, 2018-2030 (USD MILLION)
TABLE 322. INDIA ULCERATIVE COLITIS MARKET SIZE, BY MIDDLE-AGED, 2018-2030 (USD MILLION)
TABLE 323. INDIA ULCERATIVE COLITIS MARKET SIZE, BY YOUNG ADULTS, 2018-2030 (USD MILLION)
TABLE 324. INDIA ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 325. INDIA ULCERATIVE COLITIS MARKET SIZE, BY CHILDREN, 2018-2030 (USD MILLION)
TABLE 326. INDIA ULCERATIVE COLITIS MARKET SIZE, BY INFANTS, 2018-2030 (USD MILLION)
TABLE 327. INDIA ULCERATIVE COLITIS MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 328. INDIA ULCERATIVE COLITIS MARKET SIZE, BY GENERIC DRUGS, 2018-2030 (USD MILLION)
TABLE 329. INDIA ULCERATIVE COLITIS MARKET SIZE, BY PRESCRIPTION MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 330. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. INDIA ULCERATIVE COLITIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 332. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 333. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 334. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INTEGRIN AGENTS, 2018-2030 (USD MILLION)
TABLE 335. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 336. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY IL-12 AND IL-23 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 337. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 338. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 339. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 340. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 341. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY INDUCTION THERAPY, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY MAINTENANCE THERAPY, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY SURGICAL TREATMENT

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA

Methodology

Loading
LOADING...

Related Topics

Related Reports

Ulcerative Colitis Therapeutics - Global Strategic Business Report - Product Image

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033 - Product Image

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Ulcerative Colitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Ulcerative Colitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 99 Pages
  • Global
From
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Ulcerative Colitis Market Report 2025 - Product Image

Ulcerative Colitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Ulcerative Colitis Drug Market

The Ulcerative Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat a variety of gastrointestinal disorders. Ulcerative Colitis Drugs are used to treat the chronic inflammatory bowel disease of the same name. These drugs are typically administered orally or intravenously, and can be used to reduce inflammation, improve symptoms, and induce and maintain remission. Commonly prescribed Ulcerative Colitis Drugs include aminosalicylates, corticosteroids, immunomodulators, and biologics. The Ulcerative Colitis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Pfizer, Takeda, Janssen, and UCB. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.